Evidence map›Paper›PMID 34413639›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2021

CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care.

Rachel Pullen, Marc Miravitlles, Anita Sharma, Dave Singh, Fernando Martinez, John R Hurst, Luis Alves, Mark Dransfield, Rongchang Chen, Shigeo Muro and 13 more

Open access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Observational
  14. Structured Evaluation and Management of Patients with COPD in an Accredited Program.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 8 countries.

Rachel PullenObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID 0000-0002-4644-9845
Marc MiravitllesPneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.ORCID 0000-0002-9850-9520
Anita SharmaPlatinum Medical Centre, Chermside, QLD, Australia.
Dave SinghDivision of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Fernando MartinezNew York-Presbyterian Weill Cornell Medical Center, New York, NY, USA.ORCID 0000-0002-2412-3182
John R HurstUCL Respiratory, University College London, London, UK.ORCID 0000-0002-7246-6040
Luis AlvesEPI Unit, Institute of Public Health, University of Porto, Porto, Portugal.
Mark DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Rongchang ChenKey Laboratory of Respiratory Disease of Shenzhen, Shenzhen Institute of Respiratory Disease, Shenzhen People's Hospital (Second Affiliated Hospital of Jinan University, First Affiliated Hospital of South University of Science and Technology of China), Shenzhen, People's Republic of China.
Shigeo MuroDepartment of Respiratory Medicine, Nara Medical University, Nara, Japan.ORCID 0000-0001-7452-9191
Tonya WindersUSA & Global Allergy & Airways Patient Platform, Vienna, Austria.
Christopher BlangoJanssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, PA, USA.
Hana MuellerovaAstraZeneca, Cambridge, UK.
Frank TrudoAstraZeneca, Wilmington, DE, USA.
Paul DorinskyAstraZeneca, Durham, NC, USA.ORCID 0000-0002-4814-0657
Marianna AlacquaAstraZeneca, Cambridge, UK.
Tamsin MorrisAstraZeneca, Luton, UK.
Victoria CarterObservational and Pragmatic Research Institute, Singapore, Singapore.
Amy CouperObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID 0000-0002-3892-3113
Rupert JonesResearch and Knowledge Exchange, Plymouth Marjon University, Plymouth, UK.ORCID 0000-0002-5463-2981
Konstantinos KostikasObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID 0000-0003-0774-3942
Ruth MurrayObservational and Pragmatic Research Institute, Singapore, Singapore.
David B PriceObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID 0000-0002-9728-9992
Observational & Pragmatic Research Institute · SGAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESCornell University · USJinan University · CNJohnson & Johnson (United States) · USManchester University NHS Foundation Trust · GBNara Medical University · JPPlymouth Marjon University · GBUniversidade do Porto · PTUniversity College London · GBUniversity of Aberdeen · GBUniversity of Alabama at Birmingham · USUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD) are managed predominantly in primary care. However, key opportunities to optimize treatment are often not realized due to unrecognized disease and delayed implementation of appropriate interventions for both diagnosed and undiagnosed individuals. The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST) is the first-of-its-kind, collaborative, interventional COPD registry. It comprises an integrated quality improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. The first step in CONQUEST was the development of quality standards (QS). The QS will be imbedded in routine primary and secondary care, and are designed to drive patient-centered, targeted, risk-based assessment and management optimization. Our aim is to provide an overview of the CONQUEST QS, including how they were developed, as well as the rationale for, and evidence to support, their inclusion in healthcare systems. Methods: The QS were developed (between November 2019 and December 2020) by the CONQUEST Global Steering Committee, including 11 internationally recognized experts with a specialty and research focus in COPD. The process included an extensive literature review, generation of QS draft wording, three iterative rounds of review, and consensus. Results: Four QS were developed: 1) identification of COPD target population, 2) assessment of disease and quantification of future risk, 3) non-pharmacological and pharmacological intervention, and 4) appropriate follow-up. Each QS is followed by a rationale statement and a summary of current guidelines and research evidence relating to the standard and its components. Conclusion: The CONQUEST QS represent an important step in our aim to improve care for patients with COPD in primary and secondary care. They will help to transform the patient journey, by encouraging early intervention to identify, assess, optimally manage and followup COPD patients with modifiable high risk of future exacerbations.

Indexed as

Pulmonary Disease, Chronic ObstructiveQuality ImprovementHumansPrimary Health CareQuality of LifeSecondary Health Careassessmentfollow-upidentificationintervention

Identifiers

PMID34413639
PMCPMC8370848
OpenAlexW3187789380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.